JUN 09, 2020 6:37 AM PDT

Peacekeeping Engineered T Cells Restore the Balance in Diabetes

WRITTEN BY: Tara Fernandez

For patients with type 1 diabetes, hope is around the corner with a new experimental therapy that uses genetically modified immune cells. Scientists at the Seattle Children's Research Institute's Center for Immunity and Immunotherapies have been granted a multi-million dollar research grant to accelerate the therapy’s path to the clinic.

In type 1 diabetes, the pancreas does not produce enough insulin to effectively regulate the body’s blood sugar levels. This is a result of a subset of white blood cells, called effector T cells, infiltrating the pancreas and destroying insulin-producing islet cells.

Without sufficient insulin, patients often feel tired, thirsty, or hungry, and lose weight despite eating normally. By the time type 1 diabetes is diagnosed, around 80 to 90 percent of the islet cells are permanently damaged.

In healthy individuals, effector T cells are kept in check by regulatory T cells, or T regs. Regulatory T cells tell the effector T cells to calm down and limit damage to tissues like the pancreas, says David Rawlings, the senior investigator leading the research.

 

 

In research published in Science Translational Medicine, Rawlings' team created a novel way of restoring the balance between T cell effectors and regulators. Here, the patient's own T cells are isolated from a blood sample and genetically modified to equip them with T reg functionality. They are then infused back into the patient where they can stop hyperactive effectors in the pancreas and shield against further damage to the pancreas.

The research team identified a specific gene that when turned on, gave T cells the specialized abilities of T regs. This genetic switch, FOXP3, was shown to make edited T cells behave very similarly to T regs in experiments using both animal models and tissue culture.

"This data offers the first proof that engineering by way of turning on FOXP3 is sufficient to make a functional Treg-like cell product," said Rawlings, adding that this landmark research finding is directly translatable to clinical use.

Rawlings and colleagues believe that this novel technology has significant advantages over current clinical interventions for type 1 diabetes and even other T reg therapies in development. Their next steps are focused on further validating the therapy and translating the research into protocols for clinical use.

"I think some in the field questioned whether our approach would actually work, and so it's gratifying to not only have proof that it works but to continue to generate data showing just how remarkably well it works."

 

Sources: Medical Xpress, Science Translational Medicine.


 

About the Author
  • Tara Fernandez has a PhD in Cell Biology and has spent over a decade uncovering the molecular basis of diseases ranging from skin cancer to obesity and diabetes. She currently works on developing and marketing disruptive new technologies in the biotechnology industry. Her areas of interest include innovation in molecular diagnostics, cell therapies, and immunology. She actively participates in various science communication and public engagement initiatives to promote STEM in the community.
You May Also Like
APR 15, 2020
Immunology
Why More Men than Women Die from COVID-19
APR 15, 2020
Why More Men than Women Die from COVID-19
As of April 9th, over 60% of deaths from COVID-19 in New York state were men. Meanwhile, as of April 6, 82% of patients ...
MAY 03, 2020
Microbiology
Understanding How Lyme Disease Persists in the Body
MAY 03, 2020
Understanding How Lyme Disease Persists in the Body
Lyme disease is a confounding illness that can be difficult to diagnose, and can cause a wide range of serious health pr ...
MAY 06, 2020
Drug Discovery & Development
Breakthrough in Antibody Treatment for COVID-19
MAY 06, 2020
Breakthrough in Antibody Treatment for COVID-19
Israeli scientists have announced significant progress in isolating an antibody that may be effective in treating those ...
MAY 23, 2020
Microbiology
The FDA Yanks Some COVID-19 Antibody Tests From the Market
MAY 23, 2020
The FDA Yanks Some COVID-19 Antibody Tests From the Market
The massive demand for diagnostic testing led the FDA to open a short window for many testing products to go to market w ...
JUL 14, 2020
Immunology
Itsy Bitsy Nanobodies to Defeat the Big Bad Coronavirus
JUL 14, 2020
Itsy Bitsy Nanobodies to Defeat the Big Bad Coronavirus
Scientists are working on developing an arsenal of nano-sized weapons in the war against COVID-19. These molecules, call ...
JUL 28, 2020
Immunology
Immune-Brain Connection in Rare Disease Puzzles Scientists
JUL 28, 2020
Immune-Brain Connection in Rare Disease Puzzles Scientists
Huntington’s disease (HD) is a rare, inherited, and incurable condition associated with the progressive degenerati ...
Loading Comments...